EndoPredict
Gene-expression prognostic test for recurrence risk in early-stage HR-positive/HER2-negative breast cancer.
- Developer
- Myriad Genetics
- Intended use
- Risk Stratification
- Cancer scope
- Breast cancer
- Specimen
- Breast tumor tissue
- Molecular modality
- RNA expression
- Current version
- Current EndoPredict service
- Evidence context
- 2 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.